250 related articles for article (PubMed ID: 37379135)
41. Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Program.
Danese S; Dignass A; Matsuoka K; Ferrante M; Long M; Redondo I; Moses R; Maier S; Hunter Gibble T; Morris N; Milch C; Abreu MT
J Crohns Colitis; 2024 Jun; ():. PubMed ID: 38869019
[TBL] [Abstract][Full Text] [Related]
42. Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Feagan BG; Rutgeerts P; Sands BE; Hanauer S; Colombel JF; Sandborn WJ; Van Assche G; Axler J; Kim HJ; Danese S; Fox I; Milch C; Sankoh S; Wyant T; Xu J; Parikh A;
N Engl J Med; 2013 Aug; 369(8):699-710. PubMed ID: 23964932
[TBL] [Abstract][Full Text] [Related]
43. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.
Timmer A; McDonald JW; Tsoulis DJ; Macdonald JK
Cochrane Database Syst Rev; 2012 Sep; (9):CD000478. PubMed ID: 22972046
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).
Blauvelt A; Kimball AB; Augustin M; Okubo Y; Witte MM; Capriles CR; Sontag A; Arora V; Osuntokun O; Strober B
Br J Dermatol; 2022 Dec; 187(6):866-877. PubMed ID: 35791755
[TBL] [Abstract][Full Text] [Related]
45. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
[TBL] [Abstract][Full Text] [Related]
46. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
[TBL] [Abstract][Full Text] [Related]
47. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.
Timmer A; Patton PH; Chande N; McDonald JW; MacDonald JK
Cochrane Database Syst Rev; 2016 May; 2016(5):CD000478. PubMed ID: 27192092
[TBL] [Abstract][Full Text] [Related]
48. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG
Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574
[TBL] [Abstract][Full Text] [Related]
49. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE; Peyrin-Biroulet L; Loftus EV; Danese S; Colombel JF; Törüner M; Jonaitis L; Abhyankar B; Chen J; Rogers R; Lirio RA; Bornstein JD; Schreiber S;
N Engl J Med; 2019 Sep; 381(13):1215-1226. PubMed ID: 31553834
[TBL] [Abstract][Full Text] [Related]
50. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
51. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.
Jairath V; Zou GY; Parker CE; MacDonald JK; AlAmeel T; Al Beshir M; Almadi MA; Al-Taweel T; Atkinson NS; Biswas S; Chapman T; Dulai PS; Glaire MA; Hoekman DR; Koutsoumpas A; Minas E; Mosli MH; Samaan M; Khanna R; Travis S; D'Haens G; Sandborn WJ; Feagan BG
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011572. PubMed ID: 28886205
[TBL] [Abstract][Full Text] [Related]
52. Methotrexate for induction of remission in ulcerative colitis.
Chande N; Wang Y; MacDonald JK; McDonald JW
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD006618. PubMed ID: 25162749
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
[TBL] [Abstract][Full Text] [Related]
54. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
55. Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies.
Friedrich S; Chua L; Adams DH; Crandall W; Zhang XC
Clin Pharmacol Ther; 2024 May; ():. PubMed ID: 38797892
[TBL] [Abstract][Full Text] [Related]
56. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Murray A; Nguyen TM; Parker CE; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD000544. PubMed ID: 32856298
[TBL] [Abstract][Full Text] [Related]
57. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
Sandborn WJ; Feagan BG; Wolf DC; D'Haens G; Vermeire S; Hanauer SB; Ghosh S; Smith H; Cravets M; Frohna PA; Aranda R; Gujrathi S; Olson A;
N Engl J Med; 2016 May; 374(18):1754-62. PubMed ID: 27144850
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.
Reich K; Rich P; Maari C; Bissonnette R; Leonardi C; Menter A; Igarashi A; Klekotka P; Patel D; Li J; Tuttle J; Morgan-Cox M; Edson-Heredia E; Friedrich S; Papp K;
Br J Dermatol; 2019 Jul; 181(1):88-95. PubMed ID: 30734266
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J
Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921
[TBL] [Abstract][Full Text] [Related]
60. Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis.
Choi D; Sheridan H; Bhat S
Ann Pharmacother; 2024 Feb; ():10600280241229742. PubMed ID: 38344998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]